Stocktoria
Greenwich LifeSciences, Inc. GLSI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-09-25
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$19.4M | -$17.6M | -$9.3M | -$8.0M | -$4.6M |
| Net income | -$19.4M | -$17.4M | -$8.9M | -$7.8M | -$4.6M |
| Operating cash flow | -$9.9M | -$7.3M | -$6.5M | -$6.2M | -$4.3M |
| Total assets | $6.2M | $4.1M | $7.0M | $13.5M | $27.2M |
| Total liabilities | $5.8M | $3.2M | $294,406 | $262,905 | $385,172 |
| Shareholders' equity | $353,217 | $908,626 | $6.7M | $13.2M | $26.8M |
| Ratios | |||||
| Return on assets | -313.3% | -425.4% | -127.1% | -58.1% | -16.8% |
| Return on equity | -5480.5% | -1916.5% | -132.7% | -59.2% | -17.0% |
| Current ratio | 1.06 | 1.28 | — | — | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001799788 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.